EMERGING EUROPE - Growth investors should look at the Central European pharmaceuticals sector, says Baring Asset Management. According to BAM, Central European pharmaceutical companies are either supplying specialist products or breaking into the generics market. Their experience and cost advantages mean they can take market share away from the multinationals.
Klaus Bockstaller, fund manager, says: “Pharmaceutical production for the old Eastern Bloc trading region was concentrated within Hungary, Yugoslavia and countries such as Poland who focused on che...
To continue reading this article...
Join Professional Pensions
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, analysis and opinion from the industry
- Receive our in-depth monthly magazine in either print or digital format
- Access our Sustainable Investment Hub covering news and opinion from thought leaders in the ESG space
- Receive important and breaking news stories selected by the Editors in our daily newsletter
- Hear from industry experts and other forward-thinking leaders
- Receive a monthly members-only newsletter with exclusive opinion pieces from leading industry experts and a feature from the magazine in advance of its release date
